Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

73.65 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,402
Open	73.65
Bid (Size)	69.87 (100)
Ask (Size)	74.16 (100)
Prev. Close	73.65
Today's Range	73.65 - 73.65
52wk Range	13.93 - 78.80
Shares Outstanding	101,192,921
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 26, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.

Via The Motley Fool

Performance

YTD	+140.8%	+140.8%
1 Month	+2.4%	+2.4%
3 Month	+69.5%	+69.5%
6 Month	+152.2%	+152.2%
1 Year	+391.3%	+391.3%

More News

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

Via The Motley Fool

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026

Via The Motley Fool

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗

May 17, 2026

Via The Motley Fool

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 05, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

April 16, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

April 14, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

April 13, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

These stocks are gapping in today's session ↗

April 13, 2026

Via Chartmill

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

April 13, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

April 10, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears ↗

April 08, 2026

Via The Motley Fool

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

March 16, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Via The Motley Fool

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Via The Motley Fool

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 19, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

February 18, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Spyre Therapeutics, Inc. - Common Stock publicly traded?

Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?

Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?

The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market

What is the current price of Spyre Therapeutics, Inc. - Common Stock?

The current price of Spyre Therapeutics, Inc. - Common Stock is 73.65

When was Spyre Therapeutics, Inc. - Common Stock last traded?

The last trade of Spyre Therapeutics, Inc. - Common Stock was at 05/26/26 04:00 PM ET

What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?

The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 7.45B

How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?

Spyre Therapeutics, Inc. - Common Stock has 7B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.